Biocon Of India To License Two Molecules In Growth Bid
This article was originally published in PharmAsia News
Executive Summary
India's Biocon plans to license two of its drugs as part of its strategy of becoming one of the top 10 global biotechs by 2020. Kiran Mazumdar-Shaw, managing director, said the firm plans to license two molecules, one an oral insulin, the other for treating rheumatoid arthritis, which she valued at $250 million each. The IN 105 insulin candidate is about to undergo Phase III trials and Biocon hopes to have it on the U.S. and EU markets by the 2010 fiscal year. With those funds, she expects Biocon to remain on track to quadruple its current size within three years. (Click here for more
|
India's Biocon plans to license two of its drugs as part of its strategy of becoming one of the top 10 global biotechs by 2020. Kiran Mazumdar-Shaw, managing director, said the firm plans to license two molecules, one an oral insulin, the other for treating rheumatoid arthritis, which she valued at $250 million each. The IN 105 insulin candidate is about to undergo Phase III trials and Biocon hopes to have it on the U.S. and EU markets by the 2010 fiscal year. With those funds, she expects Biocon to remain on track to quadruple its current size within three years. (Click here for more) "Biocon To Monetise Two $250 Million Molecules" - Daily News & Analysis (India) (12/15/08) |